Chehrazi Naveed, Cipriano Lauren E, Enns Eva A
Department of Information, Risk, and Operations Management, McCombs School of Business, The University of Texas at Austin, Austin, TX.
Management Science, Ivey Business School, Western University, London, ON, Canada.
Oper Res. 2019 May-Jun;67(3):599-904. doi: 10.1287/opre.2018.1817. Epub 2019 May 10.
Antimicrobial resistance is a significant public health threat. In the U.S. alone, 2 million people are infected and 23,000 die each year from antibiotic resistant bacterial infections. In many cases, infections are resistant to all but a few remaining drugs. We examine the case where a single drug remains and solve for the optimal treatment policy for an SIS infectious disease model incorporating the effects of drug resistance. The problem is formulated as an optimal control problem with two continuous state variables, the disease prevalence and drug's "quality" (the fraction of infections that are drug-susceptible). The decision maker's objective is to minimize the discounted cost of the disease to society over an infinite horizon. We provide a new generalizable solution approach that allows us to thoroughly characterize the optimal treatment policy analytically. We prove that the optimal treatment policy is a bang-bang policy with a single switching time. The action/inaction regions can be described by a single boundary that is strictly increasing when viewed as a function of drug quality, indicating that when the disease transmission rate is constant, the policy of withholding treatment to preserve the drug for a potentially more serious future outbreak is not optimal. We show that the optimal value function and/or its derivatives are neither nor Lipschitz continuous suggesting that numerical approaches to this family of dynamic infectious disease models may not be computationally stable. Furthermore, we demonstrate that relaxing the standard assumption of constant disease transmission rate can fundamentally change the shape of the action region, add a singular arc to the optimal control, and make preserving the drug for a serious outbreak optimal. In addition, we apply our framework to the case of antibiotic resistant gonorrhea.
抗生素耐药性是一项重大的公共卫生威胁。仅在美国,每年就有200万人感染耐药细菌感染,2.3万人死亡。在许多情况下,感染对除了少数几种剩余药物之外的所有药物都具有抗性。我们研究了只剩下一种药物的情况,并求解了一个纳入耐药性影响的SIS传染病模型的最优治疗策略。该问题被表述为一个具有两个连续状态变量的最优控制问题,即疾病流行率和药物的“质量”(对药物敏感的感染比例)。决策者的目标是在无限期内将疾病给社会带来的贴现成本降至最低。我们提供了一种新的可推广的求解方法,使我们能够通过分析全面地刻画最优治疗策略。我们证明最优治疗策略是一种具有单个切换时间的开关控制策略。行动/不行动区域可以由一个单一边界来描述,当将其视为药物质量的函数时,该边界严格递增,这表明当疾病传播率恒定时,为了在未来可能更严重的疫情爆发中保留药物而不进行治疗的策略并非最优。我们表明最优值函数及其导数既不是连续的也不是利普希茨连续的,这表明针对这类动态传染病模型的数值方法在计算上可能不稳定。此外,我们证明放宽疾病传播率恒定的标准假设可以从根本上改变行动区域的形状,在最优控制中添加一条奇异弧,并使为严重疫情爆发保留药物成为最优策略。此外,我们将我们的框架应用于耐抗生素淋病的情况。